IMC Chicago
TRVI icon

IMC Chicago’s Trevi Therapeutics TRVI Stock Holding History

IMC Chicago’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-24,324
Closed -$354K – 6803
2026
Q1 		$290K Sell
24,324
-14,503
-37% -$162K ﹤0.01% 4626
2025
Q4 		$486K Buy
38,827
+8,225
+27% +$95.1K ﹤0.01% 3504
2025
Q3 		$280K Buy
+30,602
New +$229K ﹤0.01% 3440

Other funds holding TRVI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
NFT
Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return
FLPIM
F.L. Putnam Investment Management Lynnfield, Massachusetts $8.39B AUM 37.75% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

IMC Chicago's TRVI Position: Q2 2026 in Review

IMC Chicago sold out of Trevi Therapeutics (TRVI) in Q2 2026, closing a stake of 24,324 shares — an estimated $354K sold.

IMC Chicago first reported a position in TRVI in Q3 2025 and held it in 3 quarters. The position peaked at $486K in Q4 2025. 69 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • IMC Chicago reported no remaining Trevi Therapeutics position as of Q2 2026 after selling out during the quarter.
  • IMC Chicago sold 24,324 Trevi Therapeutics shares in Q2 2026, an estimated $354K.
  • IMC Chicago first reported a position in Trevi Therapeutics in Q3 2025 and held it in 3 quarters.
  • IMC Chicago's Trevi Therapeutics position peaked at $486K in Q4 2025.
  • 69 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on IMC Chicago's 13F filing for Q2 2026, filed 6 Aug 2026.